PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34512652-2	2021	We investigated the stromal CD86+TAM/CD163+TAM (CD86/CD163) ratio as a novel prognostic biomarker for stage II-III colorectal cancer (CRC).	tam	33-36	CD86 molecule	Homo sapiens	28-32	
19378341-5	2009	Upon IFNgamma exposure, TAM purified from ovarian cancer ascites recover a M1 phenotype (IL-10(low), IL-12(high)), express high levels of CD86 and low levels of ILT3, enhance the proliferation of CD4(+) T lymphocytes and potentiate the cytotoxic properties of a MelanA-specific CD8(+) T cell clone.	tam	24-27	CD86 molecule	Homo sapiens	138-142	
33971970-5	2021	RESULTS: We first detected intra- and inter-tumoral heterogeneities between TAM subpopulations and their functions, with CD86+ TAMs playing a crucial role in tumor progression.	tam	76-79	CD86 molecule	Homo sapiens	121-125	
34512652-2	2021	We investigated the stromal CD86+TAM/CD163+TAM (CD86/CD163) ratio as a novel prognostic biomarker for stage II-III colorectal cancer (CRC).	tam	33-36	CD86 molecule	Homo sapiens	48-52	
34512652-2	2021	We investigated the stromal CD86+TAM/CD163+TAM (CD86/CD163) ratio as a novel prognostic biomarker for stage II-III colorectal cancer (CRC).	tam	43-46	CD86 molecule	Homo sapiens	48-52